Table 1 Patient demographics
Parameter | CLS | P-value | |
|---|---|---|---|
Responder | Non-responder | ||
n | 17 | 8 | |
Female | 9 | 4 | 1.0000 |
Male | 8 | 4 | |
Gestagional age (SSW) | 37 + 4 (31 + 6–40 + 1) | 38 + 1(37 + 1–40 + 0) | 0.1049 |
RACHS-1score | 3 (2–6) | 3 (2–6) | 0.2253 |
Basic Aristotle score | 10 (4–15) | 7.25 (6.5–14.5) | 0.0997 |
Cardiopulmonary bypass time (min) | 219 (0–390) | 148 (56–439) | 0.1709 |
Cross clamp time (min) | 77 (0–177) | 51 (8–173) | 0.3508 |
Subcutaneous-thoracic-ratio (%) | 21.0 (14.3–26.5) | 19.75 (14.7–27.9) | 0.6408 |
Secondary chest closure after surgery (days) | 8 (2–24) (n = 11) | 10 (2–17) (n = 4) | 0.9878 |
Start of TLV after surgery (days) | 13 (2–44) | 15 (7–24) | 1.0000 |
Age when TLV therapy was started (days) | 35 (9–228) | 37.5 (20–549) | 0.3821 |
Preoperative weight (kg) | 3.30 (1.88–4.27) | 3.20 (1.93–6.32) | 0.7487 |
Absolute weight before TLV (kg) | 4.35 (2.83–5.55) | 4.42 (2.61–5.68) | 0.8673 |
Weight above dry weight when TLV was started (%) | 131.8 (102.6–202.8) | 133.5 (113.5–154.4) | 0.8151 |
Dose of TLV administration (mg/kg) | 0.53 (0.15–1.06) | 0.49 (0.13–0.95) | 0.6204 |
Period of TLV administration (days) | 8 (1–25) | 7 (1–47) | 0.6391 |
Urinary output 24 h prior to Tolvaptan administration (ml/kg/h) | 4.15 (0.92–9.18) | 3.27 (0.54–9.40) | 0.4665 |
Urinary output 24 h after Tolvaptan administration (ml/kg/h) | 6.38 (1.20–15.41) | 2.21 (0.28–7.15) | 0.0039 |
Days on ICU after TLV administration | 15 (3–111) | 40.5 (16–139) | 0.0155 |
Death | 1 | 3 | 0.0808 |